MARKETS

BSE Prices delayed by 5 minutes... Prices as on Jun 19, 2018   ABB India 1211.1 [ -0.30% ]ACC 1285.2 [ -1.10% ]Ambuja Cements Ltd. 200 [ -1.67% ]Asian Paints Ltd. 1268.65 [ -0.63% ]Axis Bank Ltd. 516.75 [ -1.02% ]Bajaj Auto Ltd. 2849.4 [ -1.81% ]Bank of Baroda 128.2 [ -2.06% ]Bharti Airtel 371.15 [ -0.03% ]Bharat Heavy Ele 74.4 [ -2.04% ]Bharat Petroleum 413.75 [ -2.18% ]Britannia Ind. 5989.1 [ -1.43% ]Cairn India Ltd. 285.4 [ 0.90% ]Cipla 602.25 [ -0.62% ]Coal India Ltd. 273.1 [ -0.55% ]Colgate Palm. 1191.1 [ -1.00% ]Dabur India 379.25 [ -1.83% ]DLF Ltd. 195.65 [ -2.05% ]Dr. Reddy's Labs 2394.7 [ 0.61% ]GAIL (India) Ltd. 342.55 [ 1.29% ]Grasim Inds. 1011.65 [ -0.86% ]HCL Technologies 922.2 [ -1.23% ]HDFC 1826.7 [ 0.11% ]HDFC Bank 2025.4 [ 0.20% ]Hero MotoCorp 3655.65 [ -0.36% ]Hindustan Unilever L 1601.05 [ -0.55% ]Hindalco Indus. 225.7 [ -2.38% ]ICICI Bank 292 [ -0.17% ]IDFC L 48.55 [ -1.72% ]Indian Hotels Co 133.2 [ -1.11% ]IndusInd Bank 1930.25 [ -1.90% ]Infosys 1244.05 [ -1.77% ]ITC Ltd. 266.15 [ 0.76% ]Jindal St & Pwr 222.5 [ -3.05% ]Kotak Mahindra Bank 1307.15 [ -0.53% ]L&T 1314.1 [ -0.68% ]Lupin Ltd. 898.3 [ -0.44% ]Mahi. & Mahi 892.4 [ -2.23% ]Maruti Suzuki India 8868.45 [ -1.39% ]MTNL 16.65 [ -3.20% ]Nestle India 9613 [ -0.11% ]NIIT Ltd. 96 [ -3.61% ]NMDC Ltd. 107.95 [ -3.92% ]NTPC 156.2 [ -0.32% ]ONGC 164.85 [ 0.30% ]Punj. NationlBak 86.7 [ -1.92% ]Power Grid Corpo 198.35 [ -0.28% ]Reliance Inds. 995.65 [ -1.91% ]SBI 272.4 [ -1.61% ]Vedanta 224.05 [ -3.55% ]Shipping Corpn. 62.7 [ -2.49% ]Sun Pharma. 560.1 [ -1.88% ]Tata Chemicals 723.3 [ -1.42% ]Tata Global Beverage 266.45 [ -3.04% ]Tata Motors Ltd. 304.65 [ -1.33% ]Tata Steel 554.85 [ -0.69% ]Tata Power Co. 73.5 [ -2.26% ]Tata Consultancy 1825.85 [ -0.26% ]Tech Mahindra Ltd. 695.8 [ -1.99% ]UltraTech Cement 3647.25 [ -0.60% ]United Spirits 673.5 [ 1.06% ]Wipro Ltd 261.65 [ -1.49% ]Zee Entertainment En 554.5 [ -1.12% ]

News Details

You can view in detail.
Dr. Reddy’s Lab’s arm to initiate Phase 2 trial of CA-170 13/09/2017 10:27

Dr. Reddy’s Laboratories Ltd. has said that Aurigene Discovery Technologies Limited, a wholly owned subsidiary of the company plans to initiate a Phase 2 trial of CA-170, a PDL1-VISTA inhibitor to be conducted at sites in India.

This was announced following the presentation of preliminary data from the initial 34 patients with cancer treated in the dose escalation stage of the Phase 1 trial of CA-170 at the European Society for Medical Oncology (ESMO) 2017 Congress by Aurigene’s collaborator and licensee of CA-170, Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer.

“The trial has been conducted in the U.S., South Korea and Spain. The Phase 2 trial is the result of the initial safety data and preliminary evidence of clinical benefit observed in the trial,” the company said in a filing to the Bombay Stock Exchange.

Meanwhile, shares of the company were trading at Rs 2197.05 apiece, up 1.49 per cent from the previous close at 10:33 hours on BSE.

LOAD MORE